更多开发者作品
The Lancet Haematology
| 1. | [Clinical Picture] Zanubrutinib-associated ecchymotic lesions | Samy Belkaïd, Mona Amini-Adle | |
| 2. | [In Focus] Environmental impact of haematology care—measurement and mitigation | Stephen Thomas, Stephen P Hibbs, Andrew Hantel | |
| 3. | [Correspondence] Urgent need: evidence-based use of donor lymphocyte infusions | Jaap Jan Boelens, Michael Scordo | |
| 4. | [In Focus] Second allogeneic stem-cell transplantation or donor lymphocyte infusion in patients who relapse after transplantation? | Marie Robin, Christof Scheid | |
| 5. | [Editorial] Oncology service priorities for the new UK Government | The Lancet Haematology | |
| 6. | [Editorial] New insights into pregnancy after stem-cell transplantation | The Lancet Haematology | |
| 7. | [Comment] Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List | Glenn F Pierce, Brian O'Mahony, Radoslaw Kaczmarek, Mark W Skinner, Mike Makris, Flora Peyvandi, Alok Srivastava, Cedric Hermans, World Federation of Hemophilia Coagulation Products Supply, Safety, and Access Committee (CPSSAC) | |
| 8. | [Articles] Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study | Alex F Herrera, Jasmine Zain, Kerry J Savage, Tatyana Feldman, Jonathan E Brammer, Lu Chen, Sandrine Puverel, Leslie Popplewell, Lihua Elizabeth Budde, Matthew Mei, Chitra Hosing, Ranjit Nair, Lori Leslie, Shari Daniels, Lacolle Peters, Stephen Forman, Steven Rosen, Larry Kwak, Swaminathan P Iyer | |
| 9. | [Comment] Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV–CHP? | Edith Julia, Emmanuel Bachy | |
| 10. | [Articles] Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial | Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, Rami S Komrokji, Jake Shortt, David Valcárcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Richard Pilot, Sandra Kreitz, Veronika Pozharskaya, Karen L Keeperman, Shelonitda Rose, Thomas Prebet, Yinzhi Lai, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Pierre Fenaux, Uwe Platzbecker | |
| 11. | [Comment] A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes | Yazan F Madanat, Amy E DeZern | |
| 12. | [Articles] Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study | William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann, Catherine C Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A Eyre, Joanna M Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S Tam, Wojciech Jurczak, Koji Izutsu, Alvaro J Alencar, Manish R Patel, John F Seymour, Jennifer A Woyach, Philip A Thompson, Paolo B Abada, Caleb Ho, Samuel C McNeely, Narasimha Marella, Bastien Nguyen, Chunxiao Wang, Amy S Ruppert, Binoj Nair, Hui Liu, Donald E Tsai, Lindsey E Roeker, Paolo Ghia | |
| 13. | [Review] Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies | Niels W C J van de Donk, Ajai Chari, Maria Victoria Mateos | |
| 14. | [Articles] Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial | María Díez-Campelo, Félix López-Cadenas, Blanca Xicoy, Eva Lumbreras, Teresa González, Mónica del Rey González, Joaquín Sánchez-García, Rosa Coll Jordà, Bohrane Slama, Jose-Ángel Hernández-Rivas, Sylvain Thepot, Teresa Bernal, Agnès Guerci-Bresler, Joan Bargay, María Luz Amigo, Claude Preudhomme, Laurene Fenwarth, Uwe Platzbecker, Katharina S Götze, Ali Arar, Sofía Toribio, Consuelo Del Cañizo, Jesús María Hernández-Rivas, Pierre Fenaux | |
| 15. | [Comment] Overcoming the unmet need of Richter transformation: the use of pirtobrutinib | Tamar Tadmor | |
| 16. | [Comment] SintraREViewed: practice changing, or validation required? | Rena Buckstein | |
更新于 52 分钟前
近期历史最近 100 条记录
| 2024-08-23 | [Clinical Picture] Zanubrutinib-associated ecchymotic lesions | Samy Belkaïd, Mona Amini-Adle | |
| 2024-08-23 | [In Focus] Environmental impact of haematology care—measurement and mitigation | Stephen Thomas, Stephen P Hibbs, Andrew Hantel | |
| 2024-08-23 | [Correspondence] Urgent need: evidence-based use of donor lymphocyte infusions | Jaap Jan Boelens, Michael Scordo | |
| 2024-08-23 | [In Focus] Second allogeneic stem-cell transplantation or donor lymphocyte infusion in patients who relapse after transplantation? | Marie Robin, Christof Scheid | |
| 2024-08-23 | [Editorial] Oncology service priorities for the new UK Government | The Lancet Haematology | |
| 2024-08-23 | [Editorial] New insights into pregnancy after stem-cell transplantation | The Lancet Haematology | |
| 2024-08-23 | [Comment] Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List | Glenn F Pierce, Brian O'Mahony, Radoslaw Kaczmarek, Mark W Skinner, Mike Makris, Flora Peyvandi, Alok Srivastava, Cedric Hermans, World Federation of Hemophilia Coagulation Products Supply, Safety, and Access Committee (CPSSAC) | |
| 2024-08-23 | [Comment] Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV–CHP? | Edith Julia, Emmanuel Bachy | |
| 2024-08-23 | [Articles] Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study | Alex F Herrera, Jasmine Zain, Kerry J Savage, Tatyana Feldman, Jonathan E Brammer, Lu Chen, Sandrine Puverel, Leslie Popplewell, Lihua Elizabeth Budde, Matthew Mei, Chitra Hosing, Ranjit Nair, Lori Leslie, Shari Daniels, Lacolle Peters, Stephen Forman, St | |
| 2024-08-23 | [Articles] Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial | Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, Rami S Komrokji, Jake Shortt, David Valcárcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Richard Pilot, Sandra Krei | |
| 2024-08-23 | [Comment] A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes | Yazan F Madanat, Amy E DeZern | |
| 2024-08-23 | [Articles] Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study | William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann, Catherine C Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A Eyre, Joanna M Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S Tam, Wojciec | |
| 2024-08-23 | [Review] Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies | Niels W C J van de Donk, Ajai Chari, Maria Victoria Mateos | |
| 2024-08-23 | [Articles] Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial | María Díez-Campelo, Félix López-Cadenas, Blanca Xicoy, Eva Lumbreras, Teresa González, Mónica del Rey González, Joaquín Sánchez-García, Rosa Coll Jordà, Bohrane Slama, Jose-Ángel Hernández-Rivas, Sylvain Thepot, Teresa Bernal, Agnès Guerci-Bresler, Joan B | |
| 2024-08-23 | [Comment] Overcoming the unmet need of Richter transformation: the use of pirtobrutinib | Tamar Tadmor | |
| 2024-08-23 | [Comment] SintraREViewed: practice changing, or validation required? | Rena Buckstein | |
| 2024-07-31 | [In Focus] Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health | Siana Nkya, Upendo Masamu, Patience Kuona, Sarah Kiguli, Aldiouma Guindo, Fred Stephen Sarfo, Obiageli Nnodu, Ambroise Wonkam, Emmanuel Balandya, Julie Makani, SickleInAfrica | |
| 2024-07-31 | [In Focus] Aaron Goodman: “people tell me they've been waiting for someone to speak up” | Emma Wilkinson | |
| 2024-07-31 | [In Focus] Needles were the least of my worries | Jo McIntyre | |
| 2024-07-31 | [Editorial] Reducing infection risk in patients with blood cancers | The Lancet Haematology | |
| 2024-07-31 | [Corrections] Correction to Lancet Haematol 2024; 11: e510–20 | | |
| 2024-07-31 | [Articles] Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study | Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi, Alphan Kupesiz, Maria Gabriela A Dias Matos, Yogi Chopra, Sunil Bhat, Ho Joon Im, Tayfun Güngör, Meng-Yao Lu, Tommaso Stefanelli, Christine Rosko, Annie St Pierre, Kari | |
| 2024-07-31 | [Comment] Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management? | Luisa Sisinni | |
| 2024-07-31 | [News] European Hematology Association 2024 Hybrid Congress | Yaiza del Pozo Martín, Emma Cookson | |
| 2024-07-31 | [Review] Diagnosis and management of Evans syndrome in adults: first consensus recommendations | Bruno Fattizzo, Monia Marchetti, Marc Michel, Silvia Cantoni, Henrik Frederiksen, Giulio Giordano, Andreas Glenthøj, Tomás José González-López, Irina Murakhovskaya, Mariasanta Napolitano, Maria-Eva Mingot, Maria Arguello, Andrea Patriarca, Simona Raso, Ni | |
| 2024-07-31 | [Comment] Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease | Akshay Sharma, Tami D John | |
| 2024-07-31 | [Articles] Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study | Kim M Linton, Umberto Vitolo, Wojciech Jurczak, Pieternella J Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Hervé Tilly, Raul Cordoba, David John Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Juan-Manuel Sanc | |
| 2024-07-31 | [Articles] Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study | Yu Hu, Xiaofan Liu, Hu Zhou, Shujie Wang, Ruibin Huang, Yi Wang, Xin Du, Jing Sun, Zeping Zhou, Zhenyu Yan, Wenming Chen, Wei Wang, Qingchi Liu, Qingshu Zeng, Yuping Gong, Jie Yin, Xuliang Shen, Baodong Ye, Yun Chen, Yajing Xu, Huiping Sun, Yunfeng Cheng, | |
| 2024-07-31 | [Comment] Sovleplenib in immune thrombocytopenia | María Eva Mingot-Castellano | |
| 2024-07-31 | [Articles] Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study | Carlos Bravo-Pérez, Ana Blanco, Nuria Revilla, Jorge Cobos, Alba Salgado-Parente, Susana Asenjo, Ramiro Méndez, Luis Marti-Bonmati, Santiago Bonanad, José C Albillos, Nerea Castro, Shally Marcellini, Paul López Sala, Maialen Lasa, José M Bastida, María S | |
| 2024-07-31 | [Comment] Anticoagulation in patients with inferior vena cava agenesia | Rafael S Cires-Drouet | |
| 2024-06-26 | [Comment] Pembrolizumab plus single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma | Kenshi Suzuki | |
| 2024-06-26 | [In Focus] The development of academic CAR T cells | Julio Delgado, Manel Juan, Gonzalo Calvo, Álvaro Urbano-Ispizua | |
| 2024-06-26 | [Clinical Picture] The evolutionary journey from essential thrombocythaemia to acute erythroid leukaemia | Oscar Borsani, Emanuela Boveri, Giacomo Riccaboni, Erica Travaglino, Daniela Pietra, Elisa Rumi | |
| 2024-06-26 | [Review] Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10 | Teresa Calimeri, Nicoletta Anzalone, Maria Giulia Cangi, Paolo Fiore, Filippo Gagliardi, Elisabetta Miserocchi, Maurilio Ponzoni, Andrés J M Ferreri | |
| 2024-06-26 | [Articles] Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial | Alessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, Stefano Luminari, Alessandra Dondi, Federica Cavallo, Francesco Merli, Anna Marina Liberati, Natalia Cenfra, Daniela Renzi, Manuela Zanni, Carola Boccomini, Andrés J M Ferreri, Sara Rattotti, Vittorio | |
| 2024-06-26 | [Review] The origin of ferritin reference intervals: a systematic review | Judy Truong, Kanza Naveed, Daniel Beriault, David Lightfoot, Michael Fralick, Michelle Sholzberg | |
| 2024-06-26 | [In Focus] Don Thomas: leading the charge to bone marrow transplantation | Talha Burki | |
| 2024-06-26 | [In Focus] Obiageli Nnodu: sickle cell disease in Africa's largest nation | Ray Cavanaugh | |
| 2024-06-26 | [Comment] Measurable residual disease-driven therapy after radiotherapy for early-stage follicular lymphoma | Jillian R Gunther, Chelsea C Pinnix | |
| 2024-06-26 | [Comment] Evolution, and current and future role of radiotherapy in the treatment of haematological malignancies | Lena Specht | |
| 2024-06-26 | [Editorial] UK tainted blood: amplifying the voices of the victims | The Lancet Haematology | |
| 2024-06-26 | [News] Infected blood scandal linked to more than 3000 deaths | Elizabeth Gourd | |
| 2024-06-26 | [Corrections] Correction to Lancet Haematol 2024; 11: e310–11 | | |
| 2024-06-26 | [Corrections] Correction to Lancet Haematol 2024; 11: e459–70 | | |
| 2024-06-26 | [Articles] Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial | Jillian R Gunther, Jie Xu, Manoop S Bhutani, Paolo Strati, Penny Q Fang, Susan Y Wu, Bouthaina S Dabaja, Wenli Dong, Priya R Bhosale, Christopher R Flowers, Ranjit Nair, Luis Malpica Castillo, Luis Fayad, Swaminathan P Iyer, Simrit Parmer, Michael Wang, H | |
| 2024-06-26 | [Comment] Ultra-low-dose radiation for gastric MALT lymphoma | Peter Meidahl Petersen, Dorte Schou Nørøxe | |
| 2024-06-26 | [Articles] Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study | Olga Salamero, Antonieta Molero, José Antonio Pérez-Simón, Montserrat Arnan, Rosa Coll, Sara Garcia-Avila, Evelyn Acuña-Cruz, Isabel Cano, Tim C P Somervaille, Sonia Gutierrez, María Isabel Arévalo, Jordi Xaus, Carlos Buesa, Ana Limón, Douglas V Faller, F | |
| 2024-06-26 | [Articles] Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA | Mohammad K Khan, Tahseen H Nasti, Joshua Y Qian, Troy J Kleber, Jeffrey M Switchenko, Jonathan L Kaufman, Ajay J Nooka, Madhav V Dhodapkar, Zachary S Buchwald, Daby Obiekwe, Sagar Lonial, Rafi Ahmed | |
| 2024-05-24 | [In Focus] Trends, opportunities, and challenges of clinical trials for haematological diseases in China | Jianwei Qi, Lijun Liu, Jiajia Gao, Yi Yue, Zhen Song, Lei Zhang, Tao Cheng | |
| 2024-05-24 | [In Focus] Striking the right balance | Alexander Coltoff | |
| 2024-05-24 | [Corrections] Correction to Lancet Haematol 2018; 5: e232 | | |
| 2024-05-24 | [Articles] Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study | Jehan Dupuis, Emmanuel Bachy, Franck Morschhauser, Guillaume Cartron, Noriko Fukuhara, Nicolas Daguindau, René-Olivier Casasnovas, Sylvia Snauwaert, Remy Gressin, Christopher P Fox, Francesco Annibale d’Amore, Philipp B Staber, Olivier Tournilhac, Krimo B | |
| 2024-05-24 | [Correspondence] Eltrombopag–cyclosporin A in treating severe aplastic anaemia | Krishna sai Sathiamoorthy, S Manikandan | |
| 2024-05-24 | [Correspondence] Eltrombopag–cyclosporin A in treating severe aplastic anaemia – Authors' reply | Phillip Scheinberg | |
| 2024-05-24 | [Correspondence] The effects of upward revision of haemoglobin thresholds for anaemia in blood donations – Authors' reply | Katherine L Fielding, Sabine Braat, Sant-Rayn Pasricha | |
| 2024-05-24 | [Correspondence] The effects of upward revision of haemoglobin thresholds for anaemia in blood donations | Tomohiko Sato, Nelson Hirokazu Tsuno, Ryu Yanagisawa, Shin-ichiro Fujiwara | |
| 2024-05-24 | [Review] Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT | Simona Pagliuca, Christoph Schmid, Nicole Santoro, Federico Simonetta, Giorgia Battipaglia, Thierry Guillaume, Raffaella Greco, Francesco Onida, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha, Jurgen Kuball, Mette D Hazenberg, Annalisa Ruggeri, Practice Harmo | |
| 2024-05-24 | [In Focus] Step out of the shadows: a call for action for rare diseases | Francesca Granata, Rayan Bou-Fakhredin, Maria Domenica Cappellini, Irene Motta | |
| 2024-05-24 | [Editorial] Long term strategies for individuals with sickle cell disease | The Lancet Haematology | |
| 2024-05-24 | [Review] Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management | Kai Rejeski, Michael D Jain, Nirali N Shah, Miguel-Angel Perales, Marion Subklewe | |
| 2024-05-24 | [Articles] Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study | Timothy J Craig, Donald S Levy, Avner Reshef, William R Lumry, Inmaculada Martinez-Saguer, Joshua S Jacobs, William H Yang, Bruce Ritchie, Emel Aygören-Pürsün, Paul K Keith, Paula Busse, Henrike Feuersenger, Mihai Alexandru Bica, Iris Jacobs, Ingo Pragst, | |
| 2024-05-24 | [News] 50th Annual Meeting of the EBMT | Yaiza del Pozo Martín | |
| 2024-05-24 | [Articles] Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial | Banu Aygun, Adam Lane, Luke R Smart, Brígida Santos, Léon Tshilolo, Thomas N Williams, Peter Olupot-Olupot, Susan E Stuber, George Tomlinson, Teresa Latham, Russell E Ware, REACH Investigators | |
| 2024-05-24 | [Comment] Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa | Najibah A Galadanci, Julie Kanter | |
| 2024-05-24 | [Articles] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial | Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G Richardson, Noopur Raje | |
| 2024-05-24 | [Comment] Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? | Natalie Scott Callander | |
| 2024-05-24 | [Corrections] Correction to Lancet Haematol 2024; 11: e27–37 | | |
| 2024-05-01 | [In Focus] Alexis Thompson: advancing care for sickle cell disease | Udani Samarasekera | |
| 2024-05-01 | [Clinical Picture] Clotting and bleeding in Behçet's syndrome | Jagdish R Nair, Zoe J Syrimi, Caroline V Cotton, Robert J Moots | |
| 2024-05-01 | [Editorial] Universal health coverage for children with cancer | The Lancet Haematology | |
| 2024-05-01 | [Review] Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement | Marcin W Wlodarski, Adrianna Vlachos, Jason E Farrar, Lydie M Da Costa, Antonis Kattamis, Irma Dianzani, Cristina Belendez, Sule Unal, Hannah Tamary, Ramune Pasauliene, Dagmar Pospisilova, Josu de la Fuente, Deena Iskander, Lawrence Wolfe, Johnson M Liu, | |
| 2024-05-01 | [Correspondence] Diversity, equity, and inclusion in ASH guidelines – Authors’ reply | Jeremy W Jacobs, Garrett S Booth, Julie K Silver | |
| 2024-05-01 | [In Focus] Sickle cell disease in India: current status and progress | Dipty Jain, Mihir Gupta, Manisha Madkaikar, Rabindra K Jena, Naveen Khargekar, Santosh L Saraf, Lakshmanan Krishnamurti, Kalpna Gupta | |
| 2024-05-01 | [In Focus] Doggedly first-hand: a medical memoir that does not step outside itself | Catherine Lucas | |
| 2024-05-01 | [Correspondence] Diversity, equity, and inclusion in ASH guidelines | Matthew D Seftel, Deirdra Terrell, Adam Cuker, Matthew Cheung, Menaka Pai | |
| 2024-05-01 | [Viewpoint] Methodological challenges in the development of endpoints for myelofibrosis clinical trials | Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, Natasha Szuber, Alessandro Rambaldi, Olatoyosi Odenike, Nicolaus Kröger, Nico Gagelmann, Moshe Talpaz, Hagop Kantarjian, Robert Peter Gale | |
| 2024-05-01 | [Articles] Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial | Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Christoph Schmid, Stefan W Krause, Wolfgang Bethge, Edgar Jost, Uwe Platzbecker, Stefan A Klein, Jörg Schubert, Judith Niederland, Martin Kaufmann, Kerstin Schäfer- | |
| 2024-05-01 | [Comment] Transplant without salvage: cut out the middleman | Arjun Datt Law, Jonas Ingemar Mattsson | |
| 2024-05-01 | [Articles] Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study | Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore, Thomas C Shea, Mary Beth Seegars, Paul M Armistead, Kimberly A Kasow, Anne W Beaven, Christopher Dittus, James M Coghill, Katarzyna J Jamieson, Benjamin G Vincent, Willia | |
| 2024-05-01 | [Comment] The value of anti-CD30 CAR T cells in Hodgkin lymphoma | Marianne Veyri | |
| 2024-05-01 | [Articles] Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial | Mark T Gladwin, Victor R Gordeuk, Payal C Desai, Caterina Minniti, Enrico M Novelli, Claudia R Morris, Kenneth I Ataga, Laura De Castro, Susanna A Curtis, Fuad El Rassi, Hubert James Ford, Thomas Harrington, Elizabeth S Klings, Sophie Lanzkron, Darla Lile | |
| 2024-05-01 | [Comment] Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease | Emily M Limerick, Courtney D Fitzhugh | |
| 2024-05-01 | [Articles] First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial | Xiao-Peng Tian, Jun Cai, Yi Xia, Yu-Chen Zhang, Liang Wang, Pan-Pan Liu, Hui-Qiang Huang, Ya-Jun Li, Hui Zhou, Zhi-Ming Li, Jing Yang, Li-Qiang Wei, Qi-Hua Zou, Ying Huang, Jun Li, Li Ling, Wen-Long Zhong, Qing-Qing Cai | |
| 2024-05-01 | [Comment] First-line immunochemotherapy for extranodal natural killer/T cell lymphoma | Shu-Nan Qi, Ye-Xiong Li | |
| 2024-05-01 | [Corrections] Correction to Lancet Haematol 2024; 11: e216–27 | | |
| 2024-03-27 | [In Focus] Be compliant or compromise? | May Anne Cheong | |
| 2024-03-27 | [Articles] Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial | Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Courtney DiNardo, Ghayas Issa, Guillermo Montalban-Bravo, Nicholas Short, Koji Sasaki, Debra | |
| 2024-03-27 | [In Focus] Improving quality of blood transfusion practices in Nigeria | Dalhat Gwarzo, Kathleen Selleng, Halima Ismail, Kabiru Sulaiman, Sophie Reichelt, Renate Asare, Andreas Greinacher, Aisha Kuliya-Gwarzo | |
| 2024-03-27 | [Comment] Time to define and refine maintenance strategies in acute myeloid leukaemia | Chong Chyn Chua, Andrés Gómez-De León | |
| 2024-03-27 | [Editorial] Blood deserts: a vision to tackle blood inaccessibility | The Lancet Haematology | |
| 2024-03-27 | [Editorial] Sex and gender reporting advances in medicine | The Lancet Haematology | |
| 2024-03-27 | [Articles] Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study | Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti, Musa Yilmaz, Nitin Jain, Lucia Masarova, Steven Kornblau, Elias Jabbour, Guillermo Mon | |
| 2024-03-27 | [Comment] Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia | Anna Candoni | |
| 2024-03-27 | [Articles] Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial | Michiel Coppens, Steven W Pipe, Wolfgang Miesbach, Jan Astermark, Michael Recht, Paul van der Valk, Bruce Ewenstein, Karen Pinachyan, Nicholas Galante, Sandra Le Quellec, Paul E Monahan, Frank W G Leebeek, HOPE-B Investigators | |
| 2024-03-27 | [Comment] Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond | Margareth C Ozelo | |
| 2024-03-27 | [Articles] Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources | Sabine Braat, Katherine L Fielding, Jiru Han, Victoria E Jackson, Sophie Zaloumis, Jessica Xu Hui Xu, Gemma Moir-Meyer, Sophia M Blaauwendraad, Vincent W V Jaddoe, Romy Gaillard, Patricia C Parkin, Cornelia M Borkhoff, Charles D G Keown-Stoneman, Catherin | |
| 2024-03-27 | [Review] Models of care for sickle cell disease in low-income and lower-middle-income countries: a scoping review | Laura Drown, Miriam Osei, Ada Thapa, Chantelle Boudreaux, Natasha Archer, Gene Bukhman, Alma J Adler | |
| 2024-03-27 | [Comment] Defining global thresholds for anaemia: a challenging mission | Jahnavi Daru, Javier Zamora | |
| 2024-03-27 | [Corrections] Correction to Lancet Haematol 2024; 11: e114–26 | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
